Validation of National Institutes of Health Global Scoring System for Chronic Graft-Versus-Host Disease (GVHD) According to Overall and GVHD-Specific Survival  by Moon, Joon Ho et al.
Biol Blood Marrow Transplant 20 (2014) 556e563American Society for Blood
ASBMT
and Marrow TransplantationValidation of National Institutes of Health
Global Scoring System for Chronic
Graft-Versus-Host Disease (GVHD) According
to Overall and GVHD-Speciﬁc Survival
Joon Ho Moon 1, Sang Kyun Sohn 1, Anna Lambie 2,
Laura Ellis 2, Nada Hamad 2, Jieun Uhm2, Vikas Gupta 2,
Jeffrey H. Lipton 2, Hans A. Messner 2, John Kuruvilla 2,
Dennis Kim 2,*
1Department of Hematology and Medical Oncology, Kyungpook National University Hospital, Daegu,
Korea
2Allogeneic Blood and Marrow Transplantation Program, Department of Medical Oncology and
Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, CanadaArticle history:
Received 21 November 2013
Accepted 10 January 2014
Key Words:
Allogeneic stem cell
transplantation
Graft-versus-host disease
NIH global scoring system
NIH consensus criteriaFinancial disclosure: See Acknowl
* Correspondence and reprint re
PhD, Allogeneic Blood and Marrow
Hospital, University of Toronto, 61
M5G2M9.
E-mail address: dr.dennis.kim@
1083-8791/$ e see front matter Cr
rights reserved.
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
A new severity grading system for graft-versus-host disease (GVHD) was established by the National In-
stitutes of Health (NIH) consensus criteria (NCC). However, its prognostic value still needs to be validated.
Four hundred twenty-ﬁve consecutive patients who survived beyond 100 days after allogeneic stem cell
transplantation were reviewed and reclassiﬁed using NCC. GVHD-speciﬁc survival (GSS) and cumulative
incidence of relapse were compared according to the NIH global score at the onset and peak of chronic GVHD
(cGVHD). Of 346 patients with cGVHD diagnosed by the Revised Seattle Criteria, 317 patients were reclassiﬁed
according to the NCC as classic cGVHD (n ¼ 144) and overlap syndrome (n ¼ 173). The NIH global scores at
onset were mild (43.2%), moderate (42.3%), and severe (14.5%), whereas more moderate (55.5%) and severe
(31.6%) cGVHD was observed at the peak of cGVHD. With a median follow-up duration of 34 months, the
5-year GSS was signiﬁcantly worse for the severe group than the moderate/mild groups at onset and at peak:
50.9%  7.8% versus 89.7%  3.2% versus 93.5%  2.4% at onset (P < .001) and 69.1%  5.2% versus 93.2% 
2.1% versus 97.3%  2.7% at peak (P < .001). Severe NIH global score at onset and peak were conﬁrmed as a
poor prognostic factor for GSS in multivariate analysis. The cumulative incidence of relapse did not differ
among the severity groups at onset or peak. In conclusion, the new NIH global scoring system was shown to
differentiate a high-risk group of patients (with severe grade cGVHD) in terms of long-term transplant
outcomes.
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Transplantation. All rights reserved.INTRODUCTION [3]. These developments have highlighted the great need for
Graft-versus-host disease (GVHD) is a clinical syndrome
with complex and heterogeneous pathogenesis and diverse
clinical presentations. Chronic GVHD (cGVHD) has tradi-
tionally been diagnosed based on onset after 100 days post-
transplant regardless of clinical features. The Seattle group
introduced revised criteria to grade the severity of cGVHD as
limited or extensive based on clinical and laboratory features
to help determine requirements of systemic immunosup-
pression, especially for patients with extensive cGVHD [1,2].
Over the past 2 decades, the increasing use of peripheral
blood stem cells (PBSCs), alternative donors, reduced-
intensity conditioning, and the introduction of newer
immunosuppressive agents has resulted in signiﬁcant
changes in the ﬁeld of allogeneic hematopoietic stem cell
transplantation. In addition, these advances have profoundly
affected the frequency, severity, and presentation of GVHDedgments on page 563.
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14.01.010a more precise GVHD classiﬁcation tool.
In 2005, the National Institutes of Health (NIH) estab-
lished consensus criteria (NCC) to classify GVHD into various
subtypes, including classic acute, late-onset acute, classic
cGVHD, and overlap syndrome, according to clinical pre-
sentation [3]. They also proposed a tool for scoring cGVHD
organ involvement and for assessing overall severity to
provide indications for topical or systemic therapies. How-
ever, the prognostic impact of this GVHD classiﬁcation tool
on transplant outcomes is yet to be validated in an inde-
pendent cohort.
Previous studies attempted to evaluate the impact of the
NIH global score on long-term transplant outcomes, particu-
larly on overall survival (OS). Jagasia et al. [4] reported that the
NIH global score at onset and peak made no difference to the
OS,whereasArora et al. [5] showeda trendofworse survival in
the cGVHD patients graded as severe when compared with
those graded as mild or moderate (85.1% versus 57.3%, P ¼ .1).
Perez-Simon et al. [6] also reported that severe cGVHD
adversely inﬂuenced OS compared with mild and moderate
cGVHD at 5 years (46% versus 83% and 77%, P ¼ .001).
Accordingly, the present study attempted to reclassify
cGVHD diagnosed with the Revised Seattle Criteria (RSC)
using the NCC, to evaluate transplant outcomes of cGVHDc. on behalf of American Society for Blood and Marrow Transplantation. All
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NIH global score of cGVHD on long-term outcomes after
allogeneic hematopoietic stem cell transplantation.
METHODS
Patients and Transplant Procedures
Four hundred twenty-ﬁve consecutive patients who received allogeneic
hematopoietic stem cell transplantation between January 2000 and October
2007 at the Princess Margaret Hospital, Toronto, Canada and survived at least
100 days after transplantationwere retrospectively reviewed. After excluding
79 patients who did not exhibit any evidence of cGVHD, 346 patients with
cGVHD by RSC were included in the ﬁnal analysis (Supplemental Figure 1).
Three-hundred seventeen patients with classic cGVHD or overlap syndrome
had their global severity graded according to the NCC at onset and at peak.
The study was approved by the Research Ethics Board at the University
Health Network, Toronto, Canada. Patient and transplant characteristics are
summarized in Table 1. The transplantation procedures and post-Table 1
Patient and Transplantation Characteristics (N ¼ 346)
Number Percent
Gender
Male 213 61.6
Female 133 38.4
Age at transplant, yr
Median (range) 46 (18-70)
50 136 39.3
Diagnosis
Acute leukemia (AML/ALL) 160 46.2
Chronic leukemia (CML/CLL) 73 21.1
Lymphoma (NHL/HL) 48 13.9
Myelodysplastic syndrome 27 7.8
Primary myeloﬁbrosis 22 6.4
Severe aplastic anemia 8 2.3
Others 8 2.3
Conditioning regimen
Myeloablative 256 74.0
Reduced intensity 90 26.0
HLA matching status
HLA identical sibling 249 72.0
Other related 29 8.4
Well-matched unrelated 65 18.8
Partially matched unrelated 3 .9
Stem cell source
PBSC 247 71.4
BM 99 28.6
GVHD prophylaxis
CSA based 334 96.5
Tacrolimus based 12 3.5
In vivo T cell depletion
Campath 24 6.9
ATG 4 1.2
Donor gender
Male 153 44.2
Female 177 51.2
Unknown 16 4.6
CMV status
Donor ()/recipient () 104 30.1
Donor ()/recipient (þ) 55 15.9
Donor (þ)/recipient () 43 12.4
Donor (þ)/recipient (þ) 115 33.2
Unknown 29 8.4
Acute GVHD
Grades II to IV 261 75.4
Grades III to IV 101 29.2
Chronic GVHD by RSC
Limited 108 31.2
Extensive 238 68.8
GVHD by NCC
Classic cGVHD 144 41.6
Overlap syndrome 173 50.0
Late-onset aGVHD 29 8.4
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
CML, chronic myeloid leukemia; CLL, chronic lymphoblastic leukemia; NHL,
non-Hodgkin lymphoma; HL, Hodgkin lymphoma; BM, bone marrow; ATG,
antithymocyte globulin; CMV, cytomegalovirus.transplantation management adhered to institutional policy as previously
described [7-12].
GVHD Prophylaxis and Treatment
In most cases, the GVHD prophylaxis was a cyclosporine-based regimen
(CSA; n ¼ 334), where CSAwas used either alone (n ¼ 16) or in combination
with methotrexate (n ¼ 240) or mycophenolate mofetil (n ¼ 78). Twelve
patients received an FK506-based regimen. CSA tapering was generally
initiated at 3 months post-transplantation in patients with HLA-matched
sibling or related donors and at 6 months in patients with HLA-matched
and -mismatched unrelated donors, unless ongoing therapy of GVHD
necessitated continuation of systemic immunosuppressive treatment.
The treatment for acute GVHD (aGVHD) was as follows. First-line
treatment was oral prednisone (1 mg/kg/day). Second-line therapies were
given for steroid-refractory aGVHD, including high-dose intravenous
methylprednisolone (2 mg/kg/day), a switch to FK506 from CSA, or the
initiation of antithymocyte globulin, pentostatin, rapamycin, or mycophe-
nolate mofetil, at the physician’s discretion.
The therapy for cGVHD was decided after considering the individual
patient’s clinical status and current immunosuppression. Steroid therapy
was used as the ﬁrst-line regimen for patients not receiving immunosup-
pressants, whereas either steroids, CSA, or both agents in combination were
used for patients receiving immunosuppressants. When additional treat-
ment was needed because of refractoriness, ﬂare of GVHD, or intolerance, a
salvage regimen was introduced according to each patient’s clinical mani-
festations or toxicity proﬁles. Theses salvage regimens included azathio-
prine, hydrochloroquine, mycophenolate mofetil, FK506, or combination
therapy.
Deﬁnitions
The day of the stem cell infusion was deﬁned as day 0. aGVHD and
cGVHD were diagnosed and graded using conventional criteria and the NCC
[1,2,13]. The NCC graded the global severity of cGVHD into 3 groups. The
mild group involves only 1 or 2 organs with a maximum score of 1 in all
affected organs. Themoderate group involves (1) at least 1 organ or sitewith
clinically signiﬁcant disability with a maximum score of 2, (2) 3 or more
organs or sites with no clinically signiﬁcant functional impairment (a
maximum score of 1), or (3) a lung score of 1. The severe group indicates
major disability caused by cGVHD: a score of 3 in any organ or site or a lung
score of 2 or greater. Progression of cGVHD gradewas deﬁned as progression
from any severity category at onset to a higher category at peak, according to
the NIH global scoring system. OS was deﬁned as the time from trans-
plantation until death from any cause or last follow-up. GVHD-speciﬁc
survival (GSS) was deﬁned as the time from diagnosis of cGVHD until
death from GVHD-speciﬁc causes, including GVHD itself, infection associ-
ated with immunosuppressive treatment, or both as well as death from
secondary malignancy. Cumulative incidence of relapse (CIR) was deﬁned
according to the time from transplantation until disease progression.
Statistical Analysis
Patient characteristics and transplantation procedures were compared
according to the NIH global scoring system (ie, mild, moderate, and severe)
using chi-square tests. To identify the correlation among the severity groups
between the RSC and NCC, the Pearson correlation coefﬁcient was calcu-
lated. A logistic regression test was used to identify the factors affecting
progression within the NIH global scores. Progression from the mild to
the moderate/severe groups and from the moderate to the severe group
was analyzed separately. A factor analysis (factors with Eigenvalue > 1),
including a Varimax rotation, was also conducted to determine the existence
of a common factor structure across the pretransplant variables and cGVHD
criteria (RSC and NCC). The reliability of the common factor structure was
determined using Cronbach’s a, where values > .6 were considered to have
internal consistency reliability.
OS and GSS were analyzed using the Kaplan-Meier method, and the
groups were compared using a Log-rank test. The CIR was calculated using
the Gray method considering nonrelapse mortality as a competing risk. The
prognostic impact of clinical factors on OS and GSS was examined based on
univariate and multivariate analyses using a nonetime-dependent Cox
proportional hazard model with stepwise selection procedures. Univariate
analyses included the following variables: gender, age at transplant (<50
versus 50 years), diagnosis, conditioning regimen (myeloablative versus
reduced intensity), HLA matching status (HLA-identical sibling versus other
related versus well-matched unrelated versus partially matched unrelated),
stem cell source (bone marrow versus PBSC), GVHD prophylaxis (CSA based
versus FK506 based), gender disparity (female to male versus others),
aGVHD (grades 0 to II versus grades III to IV), cGVHD severity according to
the RSC (limited versus extensive), and the NIH global scoring system (mild
versus moderate versus severe) at onset and peak.
Table 3
Causes of Death
Causes of Death P
Relapse
n (%)
GVHD
n (%)
Other(s)
n (%)
RSC (n ¼ 98)
Limited 15 (83.3) 2 (11.1) 1 (5.6) <.001
Extensive 17 (21.3) 59 (73.8) 4 (5.0)
NIH classiﬁcation (n ¼ 98)
Classic 12 (54.5) 6 (27.3) 4 (18.2) .001
Overlap 14 (28.0) 35 (70.0) 1 (2.0)
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based GVHD prophylaxis (n ¼ 334) and in 1 patient (8.3%) with FK506-
based prophylaxis (n ¼ 12). However, the T cell depletion group was not
analyzed separately because of relatively small sample size. Factors with
P < .05 in the univariate analyses were included in the multivariate anal-
ysis. P < .05 was considered signiﬁcant. The hazard ratio (HR) and 95%
conﬁdence interval (CI) were estimated using a predetermined reference
risk of 1.0.
The SPSS software package (SPSS 18.0 Inc., Chicago, IL) was used for the
statistical analyses. The CIR analysis was carried out using the cmprsk
package from R statistical software 2.15.1 (R foundation for Statistical
Computing, Vienna, Austria; available at http://www.r-project.org).Late acute 6 (23.1) 20 (76.9) 0
NIH severity at peak (n ¼ 72)
Mild 1 (33.3) 1 (33.3) 1 (33.3) <.001
Moderate 20 (60.6) 11 (3.3) 2 (6.1)
Severe 5 (13.9) 29 (80.6) 2 (5.6)RESULTS
Reclassiﬁcation of cGVHD Using the NCC
Among the 346 patients with cGVHD, the RSC classiﬁed
108 patients (31.2%) with limited cGVHD and 238 patients
(68.8%) with extensive cGVHD. The same 346 patients were
also reclassiﬁed according to the NCC into classic cGVHD (n¼
144, 41.6%), overlap syndrome (n ¼ 173, 50.0%), and late-
onset aGVHD (n ¼ 29, 8.4%) (Table 2). The 5-year OS rate
was 78.6%  4.4% for classic cGVHD, 67.7%  3.9% for overlap
syndrome, and 37.0%  3.7% for late-onset aGVHD (P < .001).
Patients with limited cGVHD (n ¼ 108) were reclassiﬁed as
classic cGVHD (n ¼ 66, 61.1%), overlap syndrome (n ¼ 36,
33.3%), and late-onset aGVHD (n¼ 6, 5.6%), whereas patients
with extensive cGVHD (n ¼ 238) were reclassiﬁed as classic
cGVHD (n ¼ 78, 32.8%), overlap syndrome (n ¼ 137, 57.6%),
and late-onset aGVHD (n ¼ 23, 9.7%). A higher frequency of
overlap syndrome (P< .001) and late-onset aGVHD (P¼ .012)
was observed in patients with extensive cGVHD than in those
with limited cGVHD.Impact of Reclassiﬁed cGVHD Subtypes on OS and GSS
With a median follow-up duration of 34 months (range,
4 to 93months), the 5-year OS rate was signiﬁcantly better in
patients with cGVHD (67.1%  2.9%) than in patients without
cGVHD (32.2%  7.6%) (P < .001) based on the overall pop-
ulation (n ¼ 425). When cGVHD was accounted as a time-
dependent variable in the analysis, favorable impact of
cGVHD on OS was conﬁrmed by time-dependent Cox’s
regression analysis (P < .001).
The causes of death in patients with cGVHD are described
in Table 3. Among patients with limited cGVHD, relapse was
the main cause of death (83.3%), whereas GVHD (73.8%) was
the major cause of death among patients with extensive
cGVHD (P < .001). When the classiﬁcation was revised ac-
cording to the NCC, 22 of 144 patients classiﬁed as classic
cGVHD died from relapse (n ¼ 12, 54.5%), GVHD-related
death (n ¼ 6, 27.3%), and other causes (n ¼ 4, 18.2%),
whereas 50 of the 173 patients classiﬁed as overlap syn-
drome died from relapse (n¼ 14, 28.0%), GVHD-related death
(n¼ 35, 70%), and other cause (n¼ 1, 2.0%; P< .001). Patients
with severe cGVHD showed a higher rate of GVHD-relatedTable 2
Reclassiﬁcation of GVHD
RSC NIH Criteria
Classic cGVHD
(n ¼ 144, 41.6%)
Overlap Syndrome
(n ¼ 173, 50.0%)
Late-Onset
aGVHD
(n ¼ 29, 8.4%)
Limited
(n ¼ 108, 31.2%)
66 (61.1) 36 (33.3) 6 (5.6)
Extensive
(n ¼ 238, 68.8%)
78 (32.8) 137 (57.6) 23 (9.7)death than those with a mild or moderate grade at onset
(P ¼ .002) and peak (P < .001).
The 5-year OS rate was signiﬁcantly higher in patients
with limited cGVHD (73.9%  6.0%) than in those with
extensive cGVHD (64.1%  3.3%; P ¼ .017) (Figure 1A). When
analyzed according to the subtype of cGVHD, the 5-year OS
rate for classic cGVHD (81.0% 3.9%) was signiﬁcantly higher
than the rate for overlap syndrome (67.7%  3.9%; P ¼ .004)
(Figure 1B).
The 5-year GSS rate was signiﬁcantly worse in patients
with extensive cGVHD (73.3%  3.1%) than in those with
limited cGVHD (97.6%  1.7%, P < .001) (Figure 1C). When
analyzed according to the subtype of cGVHD, the 5-year GSS
rate of classic cGVHD (94.5%  2.2%) was signiﬁcantly higher
than for overlap syndrome (78.3%  3.5%; P < .001)
(Figure 1D).
Classiﬁcation of cGVHD Severity at Onset and Peak Using
the NIH Global Scoring System
For the 317 patients who were reclassiﬁed as classic
cGVHD (n ¼ 144) or overlap syndrome (n ¼ 173), the NIH
global score was assessed at 2 time points: at onset and at
peak of cGVHD (Table 4). In a subgroup of patients with
limited cGVHD (n ¼ 102), the NIH global score at peak was
observed as mild in 38 patients (37.3%), moderate in 59
(57.8%), and severe in 5 (4.9%). In a subgroup of patients with
extensive cGVHD (n ¼ 215), the NIH global score at peak was
observed as mild in 3 patients (1.4%), moderate in 117
(54.4%), and severe in 95 (44.2%). Five patients (4.9%) with
limited cGVHD were diagnosed as severe according to the
NCC, and 3 patients (1.4%) with extensive cGVHD were
identiﬁed as mild. The correlation coefﬁcient among the
severity groups between the RSC and the NCC at peak was
.548 (P< .001). In the factor analysis, the RSC cGVHD severity
and the NIH global score at onset and at peak represented an
underlying common factor structure. The internal consis-
tency among these factors was .683 according to Cronbach’s
a. It implies that the NIH global scoring system showed a
high association with the RSC severity of cGVHD.
Several clinical variables were different according to the
severity based on the NIH global scoring system
(Supplemental Tables 1 and 2). Patients graded as severe
cGVHD at onset received PBSCs more frequently (P ¼ .002),
had more frequent previous episodes of grades III to IV
aGVHD (P < .001), and had a higher proportion of worse
Karnofsky performance status (KPS< 80, P< .001) than those
graded as mild/moderate. Similarly, those graded as severe
cGVHD at peak received PBSCs more frequently (P ¼ .035),
Figure 1. OS according to the RSC (A) and to the subtype of cGVHD by NIH criteria (B) and GSS according to the RSC (C) and to the subtype of cGVHD by NIH criteria
(D). (A) Five-year OS rate was 73.9%  6.0% for patients with limited cGVHD and 64.1%  3.3% for patients with extensive cGVHD (P ¼ .017). (B) Five-year OS for
patients with classic cGVHD (81.0%  3.9%) and overlap syndrome (67.7%  3.9%) was signiﬁcantly different (P ¼ .004). (C) Five-year GSS rate was signiﬁcantly worse
for patients with extensive cGVHD (73.3%  3.1%) than for patients with limited cGVHD (97.6%  1.7%, P < .001). (D) Five-year GSS rate for patients with classic cGVHD
(94.5%  2.2%) and overlap syndrome (78.3%  3.5%) was signiﬁcantly different (P < .001).
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male recipients (P ¼ .041), had more frequent previous epi-
sodes of grades III to IV aGVHD (P ¼ .003), and had a higher
proportion of worse KPS (<80, P< .001) than those graded as
mild/moderate.
In the univariate analyses, higher risk of progression to a
more advanced stage in patients initially diagnosed with
mild cGVHD were related to reduced-intensity conditioning
(odds ratio [OR] .313, P ¼ .006), gender disparity (OR 3.517,
P ¼ .010), previous episodes of grades II to IV aGVHD (OR
3.619, P¼ .001), previous episodes of stage 2 to 4 skin aGVHD
(OR 2.959, P ¼ .005), and overlap syndrome versus classic
cGVHD (OR 2.739, P ¼ .012). Among these variables, gender
disparity (OR 3.264; 95% CI, 1.210 to 8.805; P ¼ .019), and
previous episodes of grades II to IV aGVHD (OR 3.727; 95% CI,
1.643 to 8.455; P¼ .002) were conﬁrmed as independent risk
factors for progression from mild to advanced (moderate or
severe) severity of cGVHD in the multivariate analysis
(Supplemental Table 3). No variables were found to beTable 4
Changes within Global Severity Groups from Onset to Peak
At Onset At Peak
Mild (n ¼ 41) Moderate
(n ¼ 176)
Severe (n ¼ 100)
Mild (n ¼ 137) 41 (29.9) 67 (48.9) 29 (21.2)
Moderate (n ¼ 134) 0 109 (81.3) 25 (18.7)
Severe (n ¼ 46) 0 0 46 (100)predictive of progression from moderate to severe grade in
the univariate and multivariate analyses.Impact of the NIH Global Scoring System of cGVHD on OS
and GSS
The 5-year OS rate was signiﬁcantly worse in patients
graded as severe at both onset and peak: 48.5%  7.8% for
severe versus 70.1%  5.0% for moderate versus 83.2%  3.6%
for mild at onset (P¼ .001) and 61.5% 5.2% for severe versus
76.1%  3.9% for moderate versus 90.5%  5.3% for mild at
peak (P < .001) (Figure 2A,B). Similarly, the 5-year GSS rate
was signiﬁcantly worse in patients graded as severe at onset
and peak than in others: 50.9% 7.8% for severe versus 89.7%
 3.2% for moderate versus 93.5%  2.4% for mild at onset
(P< .001) and 69.1% 5.2% for severe versus 93.2% 2.1% for
moderate versus 97.3%  2.7% for mild at peak (P < .001)
(Figure 2C,D). No difference in GSS was noted between the
moderate and mild grades of cGVHD at onset (P ¼ .452) and
peak (P ¼ .474) (Table 5).
To determine the prognostic risk factor for OS in patients
diagnosed with cGVHD by the NCC, various clinical candidate
factors were evaluated as well as the severity of cGVHD ac-
cording to the RSC and the NIH global score at onset and peak.
In the univariate analyses, the following variables were sig-
niﬁcant: HLAmatch status (partially matched unrelated versus
others, P ¼ .020), aGVHD (grades 0 to II versus grades III to IV,
P < .001), KPS at cGVHD onset (80 versus <80, P < .001),
platelet count at cGVHD onset (100 versus <100  109/L,
P < .001), the NIH global score (mild/moderate versus severe)
Figure 2. OS according to NIH severity at onset (A) and at peak (B) and GSS according to NIH severity at onset (C) and at peak (D). (A) Five-year OSrate was
signiﬁcantly worse for severe global severity at onset: 48.5%  7.8% for severe versus 70.1%  5.0% for moderate versus 83.2%  3.6% for mild (P ¼ .001). Difference
between mild and moderate groups was modest (P ¼ .064). (B) Five-year OS rate was signiﬁcantly worse for severe global severity at peak: 61.5%  5.2% for severe
versus 76.1%  3.9% for moderate versus 90.5%  5.3% for mild (P < .001). No difference was observed between mild and moderate groups (P ¼ .151). (C) Five-year GSS
rate at onset was signiﬁcantly worse for patients with severe global severity (50.9%  7.8%) than for patients with moderate (89.7%  3.2%) and mild (93.5%  2.4%,
P < .001) grades. No differences in GSS was noted between moderate and mild grades of cGVHD at onset (P ¼ .452). (D) Five-year GSS rate at onset was signiﬁcantly
inferior for patients with severe global severity (69.1%  5.2%) than for patients with moderate (93.2%  2.1%) and mild (97.3%  2.7%, P < .001) grades. No differences
in GSS were noted between moderate and mild grades of cGVHD at peak (P ¼ .474).
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cation (limited versus extensive, P ¼ .019) (Supplemental
Table 4). Meanwhile, in the multivariate analyses, grades III
to IV aGVHD, severe cGVHD at onset (HR 2.298; 95% CI, 1.331
to 3.970; P ¼ .003) and peak (HR 1.648; 95% CI, 1.019 to 2.663;
P ¼ .042), KPS < 80 at cGVHD onset (HR 2.705; 95% CI, 1.217 to
3.472; P ¼ .007), and the platelet count at cGVHD onset (HR
3.459; 95% CI, 2.071 to 5.777; P < .001) were all found to be
independent factors predicting a worse OS rate (Table 5A).
However, extensive severity of cGVHD according to the RSC
was not conﬁrmed as an independent risk factor in the
multivariate analysis for OS (HR 1.070; 95% CI, .599 to 1.914;
P ¼ .819).
Various clinical factors of cGVHD classiﬁed according to
the RSC and the NIH global score at onset and peak were
evaluated to determine the risk factors predicting GSS. In
the univariate analyses, the following variables were found
to be signiﬁcant: HLA matching status, gender disparity
(female donor to male recipient versus others, P ¼ .023),
aGVHD (grades 0 to II versus grades III to IV, P < .001), KPS
at cGVHD onset (80 versus <80, P < .001), platelet count at
cGVHD onset (100 versus <100  109/L, P < .001), the
NIH global score (mild/moderate versus severe) at onset
(P < .001) and peak (P ¼ .020), and the RSC classiﬁcation
(limited versus extensive, P ¼ .001) (Supplemental Table 4).Meanwhile, in the multivariate analyses, gender disparity
(HR 2.311; 95% CI, 1.168 to 4.573; P ¼ .016), KPS < 80 at
cGVHD onset (HR 2.842; 95% CI, 1.247 to 6.478; P¼ .013), the
platelet count at cGVHD onset (HR 4.692; 95% CI, 2.252 to
9.777; P < .001), and severe cGVHD at onset (HR 5.177; 95%
CI, 1.974 to 13.575; P ¼ .001) and at peak (HR 3.798; 95% CI,
1.788 to 8.068; P ¼ .001) were all found to be independent
factors predicting a worse GSS rate (Table 5B).
Impact of Reclassiﬁed cGVHD Subtypes and NIH Global
Scoring System on CIR
The CIR for patients without cGVHD (n ¼ 79, 5-year CIR
59.5%  8.9%) was signiﬁcantly higher than that for those
with cGVHD (n ¼ 346, 5-year CIR 17.4%  .6%, P < .001).
Among patients with cGVHD, the 5-year CIR was signiﬁ-
cantly higher for limited cGVHD (23.1%  .2%) than for
extensive cGVHD (11.9%  .1%) according to the RSC (P ¼
.002) (Figure 3A). However, no difference in the CIR was
observed according to the cGVHD subtype by the NCC clas-
siﬁcation or the NIH global score at onset and peak. The 5-
year CIR rates were 21.3%  2.0% for classic cGVHD and
14.1%  .9% for overlap syndrome (P ¼ .228) (Figure 3B).
When comparing the NIH global score groups, the 5-year CIR
rates were 11.7%  .9%, 19.3% 1.4%, and 9.6%  2.2% at onset
(P ¼ .129) and 11.7%  .9%, 19.3%  1.4%, and 9.6%  2.2% at
Table 5
Multivariate Analysis of Factors Affecting OS and GSS in Patients Who Develop cGVHD
NIH Severity at Onset NIH Severity at Peak RSC
HR 95% CI P HR 95% CI P HR 95% CI P
A. Overall survival
HLA disparity and donor status
HLA identical sibling 1.000 1.000 1.000
Other related .974 .455-2.086 .947 .928 .434-1.987 .848 .958 .445-2.063 .913
Well-matched unrelated .882 .441-1.761 .721 .722 .367-1.422 .347 .726 .369-1.425 .352
Partially matched unrelated 2.827 .644-12.410 .169 3.020 .699-13.043 .139 3.305 .766-14.255 .109
Acute GVHD, n (%)
Grades 0 to II 1.000 1.000 1.000
Grades III to IV 1.822 1.113-2.981 .017 1.916 1.175-3.125 .009 2.002 1.231-3.257 .005
RSC
Limited 1.000
Extensive 1.070 .599-1.914 .819
NIH severity
Mild 1.000 1.000
Moderate 1.283 .710-2.317 .409 1.873 .574-6.115 .299
Severe 2.705 1.376-5.317 .004 2.883 .878-9.466 .081
KPS
80 1.000 1.000 1.000
<80 2.056 1.217-3.472 .007 2.396 1.462-3.928 .001 2.654 1.633-4.313 < .001
Platelet counts (109/L)
100 1.000 1.000 1.000
<100 3.459 2.071-5.777 < .001 3.174 1.900-5.301 < .001 3.243 1.946-5.406 < .001
B. GVHD-speciﬁc survival
HLA disparity and donor status
HLA identical sibling 1.000 1.000 1.000
Other related 1.325 .537-3.271 .542 1.297 .519-3.241 .577 1.257 .519-3.041 .613
Well-matched unrelated .730 .202-2.636 .631 .491 .140-1.715 .265 .404 .117-1.393 .151
Partially matched unrelated 2.461 .499-12.145 .269 2.859 .574-14.245 .200 4.130 .900-18.943 .068
Gender disparity
Others 1.000 1.000 1.000
Female/ male 2.311 1.168-4.573 .016 2.235 1.110-4.500 .024 1.546 .737-3.243 .249
Acute GVHD, n (%)
Grades 0 to II 1.000 1.000 1.000
Grades III to IV 2.022 .952-4.295 .067 2.075 .985-4.371 .055 2.565 1.263-5.208 .009
RSC
Limited 1.000
Extensive 9.237 1.260-67.720 .029
NIH severity
Mild 1.000 1.000
Moderate .945 .340-2.623 .913
Severe 5.177 1.974-13.575 .001 3.798 1.788-8.068 .001
KPS
80 1.000 1.000 1.000
<80 2.842 1.247-6.478 .013 3.746 1.794-7.825 <.001 4.241 2.065-8.709 < .001
Platelet counts (109/L)
100 1.000 1.000 1.000
<100 4.692 2.252-9.777 < .001 3.098 1.382-6.945 .006 2.675 1.259-5.682 .010
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tively (Figure 3C,D).
DISCUSSION
The current study demonstrated that the NIH global
scoring system could stratify patients with cGVHD according
to their long-term outcomes, including OS and GSS. Patients
with a severe grade had inferior long-term outcomes
compared with those with a mild or moderate grade. How-
ever, in terms of relapse risk, no difference was found among
the 3 severity groups or classiﬁcation (classic cGVHD versus
overlap syndrome). Furthermore, gender disparity (female
donor to male recipient) and previous episodes of grades II to
IV aGVHD were suggested as predictive of progression to
advanced grades of cGVHD.
In this independent cohort, the NCCwas shown to stratify
patients effectively according to their long-term outcomes,
allowing potential use for the development of risk-stratiﬁed
treatment approaches. Severe cGVHD compared with mild/moderate grade was also found to be an independent prog-
nostic factor of OS and GSS. In addition, the NIH global
scoring system showed a high correlation with the RSC
severity groups (r2 ¼ .548) and differentiated a high-risk
cGVHD group from lower risk group, making it a practical
substitute for the RSC (Cronbach’s a ¼ .686).
In this study, the severe cGVHD group was associated
with lower OS and GSS than those with mild or moderate
grade of cGVHD. Similarly, many previous retrospective and
prospective studies have shown that severe cGVHD is asso-
ciated with lower OS or GSS and higher nonrelapse mortality
[5,14-18]. Therefore, severe cGVHD can be a poor prognostic
factor correlating well with long-term outcomes. However, a
survival difference between the mild and moderate cGVHD
groups is yet to be determined. A study by Kim et al. [14]
showed a signiﬁcant GSS difference between mild and
moderate cGVHD at peak, but others did not [15,18]. This
difference might be explained by the heterogeneous nature
of moderate cGVHD, which includesmore than 3 organs with
Figure 3. (A) Five-year CIR was signiﬁcantly higher for patients with limited cGVHD (23.1%  .2%) than for patients with extensive cGVHD (11.9%  .1%, P ¼ .002). (B)
Five-year CIR was 17.3%  1.3% for classic cGVHD and 12.5%  .7% for overlap syndrome (P ¼ .228). (C) Five-year CIRs at onset among NIH severity groups were 11.7% 
.9% for mild, 19.3%  1.4% for moderate, and 9.6%  2.2% for severe (P ¼ .129). (D) Five-year CIRs at peak among NIH severity groups were 11.7%  .9% for mild, 19.3% 
1.4% for moderate, and 9.6%  2.2% for severe (P ¼ .203).
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lung involvement. Any subgroup within moderate cGVHD
may confer a better prognosis than others. Further studies
are needed to evaluate the long-term outcomes of these 3
subgroups within the moderate cGVHD category.
Few studies have evaluated relapse rates using the NIH
global scoring system, with 1 study reporting a 3-year
relapse incidence of 12% for classic cGVHD and 16% for
overlap syndrome [19]. Similarly, the present study also
showed no difference in the 5-year CIR rate between classic
cGVHD and overlap syndrome (Figure 3B). Furthermore, the
incidence of relapse was not different among the groups of
NIH global score at onset and peak, yet the limited cGVHD
group according to the RSC showed a signiﬁcantly higher
incidence of relapse than the extensive cGVHD group.
The NCC overlap syndrome showed inferior long-term
outcomes regarding OS and GSS yet a similar relapse rate
compared with classic cGVHD. In this study population, a
slightly higher proportion of patients were classiﬁed as
overlap syndrome (n ¼ 173, 50.0%) than classic cGVHD
(n ¼ 144, 41.6%). There is a signiﬁcantly lower OS rate in
overlap syndrome than in classic cGVHD (Figure 1B). Patients
with extensive cGVHD according to the RSC tend to be
diagnosed as overlap syndrome (n ¼ 137, 57.6%) compared
with those with limited cGVHD (n ¼ 36, 33.3%). This can be
explained by the fact that a signiﬁcantly higher proportion of
patients categorized as overlap syndrome progressed from
mild cGVHD at presentation to advanced severities (moder-
ate or severe) than did those categorized as classic cGVHD(81.0% versus 60.8%, P¼ .010). This explains the higher rate of
GVHD-related death among the patients with overlap syn-
drome (Table 4).
Comparative data of transplant outcomes between
classic cGVHD and overlap syndrome were reported but
with inconsistent results [4,5,14,15,18]. The incidence of
overlap syndrome and the related outcomes were reported
differently among previous studies [4,5,14-18]. In studies
using PBSCs as the predominant source of stem cells, the
incidence of overlap syndromewas higher than that in those
using bone marrow predominantly [4,5,14,15,18]. Jagasia
et al. [4] reported a 3-year OS rate of 47.2% for patients with
acute features of GVHD and 66.7% for patients with classic
cGVHD (P ¼ .015). The 5-year GSS rates have also been re-
ported as inferior for overlap syndrome (70.2%) when
compared with classic cGVHD (87.3%, P ¼ .006) [14]. Jagasia
et al. [4] suggested that acute features occurring after 100
days post-transplant had poor prognostic signiﬁcance.
Furthermore, the prospective study by Kuzmina et al. [19]
reported signiﬁcantly more patients with overlap syn-
drome had progressive onset of cGVHD (62%) than those
with classic cGVHD (7%). This resulted in worse survival
associated with higher nonrelapse mortality. In contrast, the
studies by Cho et al. [15] and Arora et al. [5] reported no
difference in survival between classic cGVHD and overlap
syndrome (3-year OS 75% versus 87%, respectively). It is not
easy to compare the results directly because patient char-
acteristics and transplantation procedures were not iden-
tical among the studies [4,5,14-18]. The inferior outcomes
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higher GVHD-related deaths in overlap syndrome than in
classic cGVHD (Figure 1). Nevertheless, overlap syndrome
seems to retain comparable graft-versus-leukemia effects
considering its similar relapse rate to that of classic cGVHD
(Figure 3).
In this study, gender disparity from a female donor to a
male recipient and previous episodes of grades II to IV
aGVHD were predictive of progression in patients with
mild cGVHD. Nevertheless, the real beneﬁts of initiating
systemic therapy for patients with these risk factors need
to be investigated further, because no differences in OS
(5-year OS rate, 81.0%  4.4% versus 76.1%  3.9, P ¼ .187)
or GSS (5-year GSS rate, 92.5%  .3% versus 89.7%  3.2%,
P ¼ .191) were found between patients with mild grades at
onset who progressed to severe grades and patients with
moderate grades at onset. However, patients with mild
cGVHD were not a homogenous population, as some had
been previously classiﬁed as extensive cGVHD according to
the RSC, which required systemic therapy. Furthermore,
the effects and responses to steroids relating to suppres-
sion of progression to more advanced grades and survival
beneﬁts need to be further evaluated using a more ho-
mogeneous population or through a prospective manner.
Another important point to address is that although sur-
vival was a major endpoint in the present study, other
endpoints such as disability, functional status, quality of
life, and need for immunosuppression are worthy to be
included when validating the NIH scoring system. Thus,
prospective cohort studies and standardized data collection
in transplant studies and clinical practice are strongly
warranted.
In conclusion, this study successfully validated the NIH
global scoring system of cGVHD, which was able to predict
the long-term outcomes for patients with cGVHD. The
impact of the NIH global score on relapse incidence needs to
be further evaluated in future studies.
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